The Society of Nuclear Medicine’s campaign to guide advanced molecular imaging techniques into clinical practice has passed the halfway point in its goal of collecting $5 million to fund the effort.
The Society of Nuclear Medicine's campaign to guide advanced molecular imaging techniques into clinical practice has passed the halfway point in its goal of collecting $5 million to fund the effort.
The SNM announced in March that donors had pledged $3.3 million. The money will support a five-year action plan to move molecular imaging research from bench to bedside. The plan proposes strategies to nuture promising MI techniques as they progress from early laboratory development to adoption in medical practice.
To coordinate that effort, the SNM has hired Marybeth Howlett as director of its Molecular Imaging Center of Excellence. Howlett was the founding executive director of the Public Health Policy Advisory Board, a nonpartisan group created by former Secretary of Health and Human Services Louis W. Sullivan in Washington, DC.
The center has several development efforts pending:
The campaign's successful fund-raising efforts since June 2006 underscore the program's importance, according to SNM President Dr. Martin P. Sandler.
"We are pleased that innovative corporate leaders believe in SNM and support its mission," he said.
Molecular imaging represents a unique departure from traditional anatomic approaches to diagnosis with medical imaging. By operating at cellular and subcellular levels, MI promises to diagnose diseases at their earliest stages to allow effective treatment, sometimes before physical symptoms and physiological damage appear.
"Molecular imaging is at the forefront of personalized medicine, which eventually will allow us to tailor the treatment of a disease to each individual patient," Sandler said.
For more information from the Diagnostic Imaging archives:
Report from SNM: Society launches Bench to Bedside molecular imaging campaign
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.